During the conduction of survival analysis within distinct subsets of age, gender, tumor location, TNM stages, differentiation grades, chemotherapy, and serum tumor markers, a remarkable inverse correlation was observed between heightened expression of RGS16 and DFS/DSS among patients diagnosed with stage II–IV CRC, patients undergoing adjuvant chemotherapy as well as moderately to poorly differentiated CRC patients (Fig. 3 and Supplementary Fig. S2A–R). Here, RGS16 is linked to colorectal carcinoma.